CEO
G. Kelly Martin
Employees
75
Industry
Pharmaceutical Preparation Manufacturing
novan, inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. we believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
July 25, 2023 | 1:05 pm
Portfolio Pulse from Benzinga Insights
July 21, 2023 | 5:31 pm
Portfolio Pulse from Benzinga Insights
July 21, 2023 | 5:24 pm
Portfolio Pulse from Benzinga Insights
July 20, 2023 | 9:32 pm
Portfolio Pulse from Benzinga Insights
July 19, 2023 | 9:32 pm
Portfolio Pulse from Lisa Levin
July 18, 2023 | 5:00 pm
Portfolio Pulse from Lisa Levin
July 17, 2023 | 7:05 pm
Portfolio Pulse from Benzinga Insights
July 17, 2023 | 5:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.